Chinese insulin market report(2006 edition)

Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published: 
Format:  Hardcopy and Adobe PDF 
Price:  US$1,500 
Contact: Mr. Bian chenghua   Ms. Wu huifang
Tel.: 86-10-68012929-2116/2101             Fax:  86-10-68012929-2008
E-mail: bianch@healthoo.com   wuhf@healthoo.com   

    In China 23.8 million people having diabetes, China comes into the 
procession of middle incidence of diabetes from low incidence. Now
 China have the most diabetic patients in the world. Insulin is a drug 
included in catalogue of drugs for basic national medical insurance�?
Now foreign and joint venture enterprises occupy the major segment of
 the Chinese insulin market. 
   
   The report presents epidemic trend of diabetes in China, Market
 shares of different enterprises (brands), sales analysis of key
 cities etc, based on the accurate data. The report also provides
 market forecasts and competitive and opportunity analysis in China. 


Summary
1 Overview of epidemic trend of diabetes in China
2 Overview of antidiabetic market in China
3 Development of insulin
  3.1 Pharmaceutical action and classification
  3.2 Current status of clinical usage
  3.3 Development process of insulin in China
4 Market analysis in Chinese insulin market
  4.1 General situation of Chines insulin market
  4.2 Sales situation of different breeds of insulin and insulin
 analogs
  4.3 Sales analysis of insulin products in different cities
  4.4 Market shares of different enterprises (brands)
    4.1.1 Novo Nordisk Biotechnology Co Ltd
    4.1.2 Suzhou lilly Pharmaceutical Co., Ltd
    4.1.3 Jiangsu Wanbang biochemical medicine Co.,LTD
    4.1.4 Shanghai No.1 Biochemical Pharmaceutical Co. Ltd	
    4.1.5 Tonghua Dongbao Pharmaceutical Company, Ltd
5 Sales analysis of different breeds
  5.1 mono component insulin (McI)
  5.2 insulin
  5.3 protamine zinc insulin
  5.4 Insulin lispro
  5.5 Insulin Aspart
6 Sales forcast and suggestions for marketing